BriaCell

BriaCell Opens 2nd Site for Ongoing Clinical Trial

BriaCell Appoints Top Oncologist and Opens Second Clinical Site for its Ongoing Clinical Trial in Advanced Breast Cancer July 31, 2017 Berkeley, CA and Vancouver, BC – July 31, 2017 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV: BCT) (OTCQB: BCTXF), an immuno-oncology focused biotechnology company with a proprietary vaccine [...]

By | 2017-07-31T15:30:09+00:00 July 31st, 2017|BriaCell|0 Comments

BriaCell Launches Its Scientific Advisory Board

BriaCell Launches Its Scientific Advisory Board ------ May 31, 2017 Berkeley, CA and Vancouver, BC – May 31, 2017 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV: BCT) (OTCQB: BCTXF), announced today the establishment of its Scientific Advisory Board (SAB) engaging a number of highly-experienced leading experts in the field of immune-oncology. Briacell [...]

By | 2017-06-01T11:45:18+00:00 May 31st, 2017|BriaCell|0 Comments

BriaCell Closes CEO Equity Investment

BriaCell Closes CEO Equity Investment  ------ March 24, 2017   BERKELEY, CA and VANCOUVER, BC–(Marketwired – March 24, 2017) – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX VENTURE: BCT) (OTCQB: BCTXF) is pleased to announce it has completed its previously announced non-brokered private placement financing (the “Offering”) of 5,612,083 units (the “Units”) for [...]

By | 2017-05-22T15:47:50+00:00 March 24th, 2017|BriaCell|0 Comments